Evidence map›Paper›PMID 25800569›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2015

[Analysis of differentially expressed proteome in urine 
from non-small cell lung cancer patients].

Zhengang Chen, Jinbo Liu, Ling Lin, Hui Xie, Wencheng Zhang, Hongbo Zhang, Guangshun Wang

Open access · greenAbstract readEnglish Abstract
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zhengang ChenDepartment of Oncology Srugery, Baodi Clinical Hospital, Tianjin Medical University, Tianjin 301800, China.
Jinbo LiuDepartment of Oncology Srugery, Baodi Clinical Hospital, Tianjin Medical University, Tianjin 301800, China.
Ling LinDepartment of Oncology Srugery, Baodi Clinical Hospital, Tianjin Medical University, Tianjin 301800, China.
Hui XieDepartment of Oncology Srugery, Baodi Clinical Hospital, Tianjin Medical University, Tianjin 301800, China.
Wencheng ZhangDepartment of Oncology Srugery, Baodi Clinical Hospital, Tianjin Medical University, Tianjin 301800, China.
Hongbo ZhangDepartment of Oncology Srugery, Baodi Clinical Hospital, Tianjin Medical University, Tianjin 301800, China.
Guangshun WangDepartment of Oncology Srugery, Baodi Clinical Hospital, Tianjin Medical University, Tianjin 301800, China.
Tianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundScreen differentially expressed proteins in patients with non-small cell lung cancer (NSCLC), and aim to identify biomarkers for early screening, monitoring prognosis and evaluating therapy of NSCLC.

methodsUrinary samples were collected from 40 newly diagnosed NSCLC patients, 8 patients with lung benign disorders and 22 healthy people. 0.9% sodium dodecylsulfate- polyacrylamide gel electrophoresis (1D SDS-PAGE) and MS-Thermo-Orbitrap-Velos were applied to separate, extract and identify proteins in urinary samples from non-neoplastic groups and NSCLC patients, in order to find out differentially expressed proteins in patients with NSCLC. Then, sensitivity and specificity of candidate proteins were tested by certain experiments. Finally, biomarkers related to NSCLC could be determined.

resultsThe differences of urinary proteins between non-neoplastic groups and NSCLC patients mainly focused on 90 kDa, 60 kDa and 20 kDa-30 kDa stripes. Four differently expressed proteins were found in urinary proteins in NSCLC group, including LRG1, CA1 (up-regulating proteins) and VPS4B, YWHAZ (down-regulating proteins). The sensitivity of these four proteins for biomarker of NSCLC was relatively low when they were used to screen or diagnose independently. The sensitivity and specificity of LRG1 was 83.0% (25/30) and 90.0% (18/20), respectively; 60.0% (18/30) and 90.0% (18/20) for CA1; 73.3% (22/30) and 90.0% (18/20) for VPS4B; 60.0% (18/30) and 95.0% (19/20) for YWHAZ. However, the sensitivity and specificity would increase to 96.7% (29/30) and 85% (17/20) after the four biomarkers were combined.

conclusionsLRG1 and CA1 are abundant in urine in patients with NSCLC, while VPS4B and YWHAZ are low-abundance proteins. They could be regarded as biomarkers for early screening, monitoring prognosis and evaluating therapy of patients with NSCLC because of differential expression. The sensitivity of the four biomarkers of NSCLC is relatively low when they are used to screen or diagnose independently, while significantly improvement if they were in combined pattern, which will be of excellent applications to clinical diagnosis and treatment.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedProteomeYoung AdultBiomarkers, TumorProteome

Identifiers

PMID25800569
PMCPMC6000009
OpenAlexW1775498466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.